• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.

作者信息

Wallis Robert S

机构信息

Aurum Institute, Johannesburg, South Africa

出版信息

Eur Respir J. 2016 Nov;48(5):1526-1527. doi: 10.1183/13993003.01207-2016.

DOI:10.1183/13993003.01207-2016
PMID:27799400
Abstract
摘要

相似文献

1
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.包括贝达喹啉、地拉曼迪和氯法齐明在内的广泛耐药结核病治疗方案的心脏安全性。
Eur Respir J. 2016 Nov;48(5):1526-1527. doi: 10.1183/13993003.01207-2016.
2
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.包括贝达喹啉、地拉曼尼和氯法齐明在内的广泛耐药结核病治疗方案的心脏安全性。
Eur Respir J. 2016 Nov;48(5):1527-1529. doi: 10.1183/13993003.01552-2016.
3
Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.贝达喹啉、地拉米啶和氯法齐明在耐多药结核病患者中的药代动力学
J Antimicrob Chemother. 2021 Mar 12;76(4):1019-1024. doi: 10.1093/jac/dkaa550.
4
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.在耐多药结核病治疗期间低水平地奈达胺和贝达喹啉耐药的出现。
Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074.
5
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.韩国耐多药和广泛耐药结核病中德拉马尼、贝达喹啉和利奈唑胺最低抑菌浓度分布及耐药相关基因突变。
Ann Lab Med. 2018 Nov;38(6):563-568. doi: 10.3343/alm.2018.38.6.563.
6
Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.贝达喹啉、德拉马尼、利奈唑胺、氯法齐明、莫西沙星和加替沙星对中国北京广泛耐药结核病的药敏性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00900-17. Print 2017 Oct.
7
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.亚美尼亚、印度和南非采用贝达喹啉与德拉马尼联合治疗耐多药结核病患者的早期安全性和疗效：一项回顾性队列研究。
Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13.
8
First case report in Latin America: Oral treatment of multidrug-resistant tuberculosis with delamanid and bedaquiline in combination with linezolid, moxifloxacin and clofazimine following a DRESS syndrome in a peruvian patient.拉丁美洲首例病例报告：秘鲁一名患者出现药物超敏反应综合征后，使用地拉马尼和贝达喹啉联合利奈唑胺、莫西沙星及氯法齐明口服治疗耐多药结核病。
Pulmonology. 2021 Jan-Feb;27(1):77-79. doi: 10.1016/j.pulmoe.2020.03.005. Epub 2020 May 20.
9
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.首例广泛耐药结核病使用德拉马尼和贝达喹啉治疗。
Eur Respir J. 2016 Sep;48(3):935-8. doi: 10.1183/13993003.00637-2016. Epub 2016 Jun 10.
10
Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.贝达喹啉与地拉米啶联合使用治疗耐多药和广泛耐药结核病的疗效及耐受性：一项系统评价和荟萃分析。
Clin Infect Dis. 2023 Apr 3;76(7):1328-1337. doi: 10.1093/cid/ciac876.

引用本文的文献

1
Pharmacokinetics and Safety of Clofazimine in Children With Rifampicin-Resistant Tuberculosis.氯法齐明在耐利福平结核病儿童中的药代动力学及安全性
J Infect Dis. 2025 Jun 2;231(5):e873-e881. doi: 10.1093/infdis/jiaf057.
2
A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease.采用氯法齐明负荷剂量以在非结核分枝杆菌病患者中迅速达到类似稳态的浓度。
J Antimicrob Chemother. 2024 Dec 2;79(12):3100-3108. doi: 10.1093/jac/dkae309.
3
Validation of a Handheld 6-Lead Device for QT Interval Monitoring in Resource-Limited Settings.
在资源有限的环境中验证用于 QT 间期监测的手持式 6 导联设备。
JAMA Netw Open. 2024 Jun 3;7(6):e2415576. doi: 10.1001/jamanetworkopen.2024.15576.
4
Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against .氯法齐明和贝达喹啉的耐药分子机制及治疗效果
Front Med (Lausanne). 2024 Jan 10;10:1304857. doi: 10.3389/fmed.2023.1304857. eCollection 2023.
5
QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.利福平耐药结核病治疗中多药方案中使用一种或多种延长 QT 间期药物导致 QT 间期延长：两项儿科研究结果。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0144822. doi: 10.1128/aac.01448-22. Epub 2023 Jun 26.
6
Clofazimine for the treatment of tuberculosis.氯法齐明用于治疗结核病。
Front Pharmacol. 2023 Feb 2;14:1100488. doi: 10.3389/fphar.2023.1100488. eCollection 2023.
7
Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.开发和验证中国贝达喹啉方案治疗患者 QT 间期延长预测列线图：一项建模研究。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0203321. doi: 10.1128/aac.02033-21. Epub 2022 Sep 1.
8
and Pulmonary Rehabilitation: From Novel Pharmacotherapeutic Approaches to Management of Post-Tuberculosis Sequelae.以及肺康复：从新型药物治疗方法到肺结核后遗症的管理
J Pers Med. 2022 Apr 2;12(4):569. doi: 10.3390/jpm12040569.
9
QT prolongation in the STREAM Stage 1 Trial.在 STREAM 阶段 1 试验中 QT 延长。
Int J Tuberc Lung Dis. 2022 Apr 1;26(4):334-340. doi: 10.5588/ijtld.21.0403.
10
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.贝达喹啉和德拉马尼治疗方案在终末期结核队列中的安全性。
Clin Infect Dis. 2022 Sep 29;75(6):1006-1013. doi: 10.1093/cid/ciac019.